Inactive Instrument

TopoTarget A/S

Equities

TOPO

DK0060003556

Biotechnology & Medical Research

TopoTarget A/S : Abstract for ASCO Gastrointestinal Cancers Symposium 2012

January 18, 2012 at 05:37 am EST

MarketScreener.com By The editorial team

Copenhagen, 2012-01-18 11:01 CET (GLOBE NEWSWIRE) --

Copenhagen, Denmark - January 18, 2012 - Today Topotarget A/S (NASDAQ OMX: TOPO.CO) announced that clinical data on belinostat will be presented at The 2012 Gastrointestinal Cancers Symposium, January 19-21, 2012.

Shown below is the abstract that is now available for viewing on the ASCO.org website (www.asco.org).

Efficacy of belinostat in advanced hepatocellular carcinoma (HCC): Phase I and II multicentered study of the Mayo Phase 2 Consortium (P2C) and the Cancer Therapeutics Research Group (CTRG).

Abstract No.: 259

Session: General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Background:
Belinostat is a novel histone deactylase inhibitor which demonstrates preclinical activity in HCC. We report the results of a phase I/II study in belinostat in patients (pts) with unresectable HCC.

Methods:
Major eligibility criteria included histologically confirmed HCC not amenable to curative treatment; PS

Latest news about TopoTarget A/S

Chart TopoTarget A/S

Duration

Period

More charts

Company Profile

Topotarget A/S is a Denmark-based biopharmaceutical company focused on the field of oncology. The Company is engaged in the development of cancer therapies, focusing primarily on the development of its principal drug candidate, Belinostat. Belinostat can be used in combination with full doses of chemotherapy, and is in a pivotal trial within peripheral T-cell lymphoma (PTCL) and phase II in cancer of unknown primary (CUP). It works in partnerships with Spectrum Pharmaceuticals Inc., Multimeric Biotherapeutics Inc. and the National Cancer Institute. As of December 31, 2011, the Company had five wholly owned subsidiaries, namely Topotarget UK Limited, Topotarget Germany AG, Topotarget USA Inc., Topotarget Switzerland S.A. and Topotarget Netherlands B.V. The Company's two largest shareholders are HealthCap funds and Avanza bank. In April 2014, combined holdings of Topotarget A/S shares for all relevant HealthCap entities (HealthCap III and HealthCap IV) were reduced below 10%.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	105B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.5B
ARGENX SE	+1.86%	22.19B
BIONTECH SE	-16.53%	21.33B
GENMAB A/S	-8.49%	18.68B
WUXI APPTEC CO., LTD.	-42.33%	16.6B
BEIGENE, LTD.	-20.09%	14.52B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	14.09B
SAREPTA THERAPEUTICS, INC.	+28.85%	10.99B

Bio Therapeutic Drugs